Amgen Inc. (AMGN)
NASDAQ: AMGN · Real-Time Price · USD
407.19
+14.03 (3.57%)
Sep 22, 2026, 12:46 PM EDT - Market open
Amgen Revenue
Amgen had revenue of $10.05B in the quarter ending June 30, 2026, with 9.53% growth. This brings the company's revenue in the last twelve months to $38.10B, up 9.10% year-over-year. In the year 2025, Amgen had annual revenue of $36.75B with 9.95% growth.
Revenue (ttm)
$38.10B
Revenue Growth
+9.10%
P/S Ratio
5.58
Revenue / Employee
$1,209,365
Employees
31,500
Market Cap
220.14B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 36.75B | 3.33B | 9.95% |
| Dec 31, 2024 | 33.42B | 5.23B | 18.57% |
| Dec 31, 2023 | 28.19B | 1.87B | 7.09% |
| Dec 31, 2022 | 26.32B | 344.00M | 1.32% |
| Dec 31, 2021 | 25.98B | 555.00M | 2.18% |
| Dec 31, 2020 | 25.42B | 2.06B | 8.83% |
| Dec 31, 2019 | 23.36B | -385.00M | -1.62% |
| Dec 31, 2018 | 23.75B | 898.00M | 3.93% |
| Dec 31, 2017 | 22.85B | -142.00M | -0.62% |
| Dec 31, 2016 | 22.99B | 1.33B | 6.14% |
| Dec 31, 2015 | 21.66B | 1.60B | 7.97% |
| Dec 31, 2014 | 20.06B | 1.39B | 7.43% |
| Dec 31, 2013 | 18.68B | 1.41B | 8.17% |
| Dec 31, 2012 | 17.27B | 1.68B | 10.80% |
| Dec 31, 2011 | 15.58B | 529.00M | 3.51% |
| Dec 31, 2010 | 15.05B | 411.00M | 2.81% |
| Dec 31, 2009 | 14.64B | -361.00M | -2.41% |
| Dec 31, 2008 | 15.00B | 232.00M | 1.57% |
| Dec 31, 2007 | 14.77B | 503.00M | 3.53% |
| Dec 31, 2006 | 14.27B | 1.84B | 14.79% |
| Dec 31, 2005 | 12.43B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 97.93B |
| Merck & Co. | 66.57B |
| AbbVie | 64.39B |
| Pfizer | 63.70B |
| AstraZeneca | 61.37B |
| Novartis AG | 56.69B |
| Sanofi | 55.89B |
| Novo Nordisk | 50.34B |
AMGN News
- 3 hours ago - Amgen's autoimmune drug succeeds in late-stage trial - Reuters
- 3 hours ago - AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE - PRNewsWire
- 7 days ago - Amgen Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 8 days ago - FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA® - PRNewsWire
- 10 days ago - Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness - WSJ
- 12 days ago - Amgen Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 12 days ago - AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE - PRNewsWire
- 13 days ago - Jim Cramer says investors are too focused on AI stocks. Here's where he says to look instead - CNBC